1. Home
  2. SCLX vs KPTI Comparison

SCLX vs KPTI Comparison

Compare SCLX & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scilex Holding Company

SCLX

Scilex Holding Company

SELL

Current Price

$3.45

Market Cap

34.4M

Sector

Health Care

ML Signal

SELL

Logo Karyopharm Therapeutics Inc.

KPTI

Karyopharm Therapeutics Inc.

HOLD

Current Price

$0.65

Market Cap

36.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCLX
KPTI
Founded
2011
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.4M
36.7M
IPO Year
2020
2013

Fundamental Metrics

Financial Performance
Metric
SCLX
KPTI
Price
$3.45
$0.65
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
★ $7.25
AVG Volume (30 Days)
28.5K
★ 1.4M
Earning Date
11-13-2026
11-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
$30,253,000.00
★ $146,067,000.00
Revenue This Year
$118.16
N/A
Revenue Next Year
$186.31
$27.98
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 0.57
52 Week Low
$3.79
$0.63
52 Week High
$27.00
$10.99

Technical Indicators

Market Signals
Indicator
SCLX
KPTI
Relative Strength Index (RSI) 22.30 17.23
Support Level N/A N/A
Resistance Level $5.60 $2.16
Average True Range (ATR) 0.37 0.17
MACD -0.10 -0.04
Stochastic Oscillator 0.93 1.44

Price Performance

Historical Comparison
SCLX
KPTI

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).

Share on Social Networks: